Certest faces the final phase of the project “Development of mRNA thermostable vaccines against SARS-COV-2 Delta variant”, which runs from January 2021 to December 2023. Animal challenge studies are currently underway and preliminary results are promising.

This project provides innovative solutions to key mRNA vaccine challenges through three approaches: in-house production of raw materials for RNA synthesis, improved delivery using proprietary ionisable lipids and formulations, and freeze-drying to facilitate preservation.

More information: https://www.stabvac4cov-project.com/

This project (MIP-20211002) has been funded by the CDTI and supported by the Spanish Ministry of Science and Innovation under the Science and Innovation Missions Programme 2021.